BLOOMFIELD, Conn., Oct. 25, 2023 /PRNewswire/ -- The Board of Directors of The Cigna Group (NYSE: CI) today declared a cash dividend of $1.23 per share of its common stock, payable on December 21, 2023 to shareholders of record as of the close of business on December 6, 2023.
About The Cigna Group
The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Cigna Healthcare, Evernorth Health Services or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 countries and jurisdictions, and has more than 190 million customer relationships around the world. Learn more at thecignagroup.com.
Investor Relations Contact
Ralph Giacobbe
1 (860) 787-7968
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Justine Sessions
1 (860) 810-6523
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$353.12 |
| Daily Change: | 4.28 1.23 |
| Daily Volume: | 1,608,722 |
| Market Cap: | US$98.710B |
September 12, 2024 September 12, 2024 August 01, 2024 May 23, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
